[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Henan Institute of Cardiovascular Epidemiology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":240},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,42,70,91,110,129,148,172,199,219],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100575205","phase-4-intracoronary-rhtnk-tpa-versus-tirofiban-in-patients-with-stemi-and-high-thrombus-burden-100575205",false,"NCT06769256","Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden","Effects of Intracoronary Recombinant Human TNK Tissue-type Plasminogen Activator Versus Tirofiban on Myocardial Perfusion and Clinical Prognosis in Patients With ST-segment Elevation Myocardial Infarction and High Thrombus Burden: a Multicenter, Randomized, Controlled, Single-blind, Non-inferior Study","H2-THROMBUS","Inclusion Criteria:\n\n* Age 18-75 years old;\n* STEMI within 12 hours of onset;\n* TIMI flow grade 0-2 or TIMI thrombus grade ≥4 after thrombus aspiration or balloon dilation\n* Radial artery access\n\nExclusion Criteria:\n\n* A functional coronary collateral supply (Rentrop grade≥2) to the infarctrelated artery\n* Known or suspected old myocardial infarction of target vessels\n* Rescue PCI\n* Cardiogenic shock\n* Contraindications to Tirofiban or rhTNK-tPA\n* Severe hepatic and renal insufficiency (alanine aminotransferase ≥5 upper limit of normal; estimated glomerular filtration rate \\\u003C30ml\u002Fmin\u002F1.73m2, or on dialysis)\n* Prolonged (\\> 10 minutes) cardiopulmonary resuscitation\n* Definite mechanical complications (including ventricular septal perforation, or rupture of the Papillary tendon bundle, or rupture of the left ventricular free wall)\n* Severe chronic obstructive pulmonary disease or respiratory failure\n* Severe infection\n* Neurological disorders\n* Malignant tumors or other pathophysiological conditions with an expected survival time of less than 1 year\n* Pregnant or lactating women","ALL","18 Years","75 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to compare the efficacy and safety of intracoronary rhTNK-tPA or Tirofiban in patients with ST-segment elevation myocardial infarction and high thrombus burden. The main questions it aims to answer are:\n\n* Is the efficacy of intracoronary rhTNK-tPA non-inferior to intracoronary Tirofiban for the treatment of ST-segment elevation myocardial infarction in patients wiht high thrombus burden?\n* Does intracoronary rhTNK-tPA increase the incidence of bleeding events?\n\nThis multicenter RCT study plans to enroll 300 patients, who are randomly divided into two groups: intracoronary rhTNK-tPA or Tirofiban by 1:1. The primary efficacy endpoint was post-PCI corrected TIMI frame count (CTFC). Major adverse events (death, recurrent myocardial infarction, ischemic stroke, or hospitalization for heart failure) were observed at 1 year follow-up.",[28],"ST-segment Elevation Myocardial Infarction (STEMI)","RECRUITING","2026-05-19",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":33},"2025-01-01",{"date":37,"type":22},"2027-12-30",{"name":39,"class":40},"Henan Institute of Cardiovascular Epidemiology","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100632510","cric-combined-with-mft-for-mfr-in-patients-with-incomplete-revascularization-of-cad-100632510","NCT07514624","CRIC Combined With MFT for MFR in Patients With Incomplete Revascularization of CAD","Chronic Remote Ischemic Conditioning Combined With Mindfulness Therapy for Myocardial Flow Reserve in Patients With Incomplete Revascularization of Coronary Artery Disease: A Multicenter, Double-blind, Randomized Controlled Trial","CRMF-MFR","Inclusion Criteria:\n\n* Age ≥18 years old\n* Consistent with the diagnosis of coronary heart disease, complete revascularization was not performed (coronary angiography showed that at least one vessel with a reference diameter of 3.0mm had stenosis greater than 90%, and quantitative flow ratio (QFR) \\\u003C 0.80)\n* Symptoms of myocardial ischemia (resting or exertional angina; Angina allele: chest tightness, shortness of breath, etc.);\n\nExclusion Criteria:\n\n* • Age \\\u003C 18 years old\n\n  * Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) \\\u003C 30%\n  * Creatinine clearance \\\u003C15 mL\u002Fmin (or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m²), or requires dialysis\n  * Myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.\n  * Uncontrolled or recurrent arrhythmic events (e.g., ventricular fibrillation, recurrent or symptomatic sustained ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular rates, supraventricular tachycardia refractory to drugs)\n  * Poorly controlled hypertension (SBP \\> 180 mm Hg or DBP \\> 110 mm Hg)\n  * Active liver disease or persistent ALT or AST elevation ≥ 3 times the upper limit of normal\n  * Unexplained CK \\> 5 times the upper limit of normal, or elevated CK due to known muscle disease\n  * Planned or anticipated cardiac surgery or revascularization before randomization\n  * History of active malignancy (surgery, radiation therapy, and\u002For systemic therapy within the past 3 years)\n  * Diagnosed or suspected upper extremity vascular malformations, aneurysms, arteriovenous fistulas, or thrombosis\n  * Hearing impairment, unable to undergo mindfulness therapy\n  * Currently participating in another drug or device study, or within 30 days of completing another drug or device study or receiving another investigational drug\n  * Any life-threatening comorbid conditions expected to result in death within the next year (excluding cardiovascular diseases)\n  * Alcoholism, substance abuse history; and unwilling or unable to stop alcohol or substance abuse during the study\n  * History of major organ transplant (e.g., lung, liver, heart, bone marrow, kidney)\n  * Investigator's judgment of known major active and uncontrolled disease, or any medical, physical, or surgical conditions (e.g., infection, significant blood, kidney, metabolic, gastrointestinal, or endocrine dysfunction) that may interfere with participation in the clinical study\n  * As known to the investigator, the subject is unlikely to complete follow-up for more than 1 year or is expected to be unable to comply with the study requirements or understand the study's objectives and potential risks.",{"count":51,"type":22},480,[53],"NA","The main objective of this study is to demonstrate whether the combination of chronic remote ischemic conditioning and mindfulness therapy can improve myocardial flow reserve in patients with incomplete revascularization of coronary artery disease.",[56],"Coronary Disease",[58,59,60],"CAD","MFR","RIPC","NOT_YET_RECRUITING","2026-04-01",{"date":64,"type":33},"2026-04-07",{"date":66,"type":22},"2026-05-01",{"date":68,"type":22},"2028-12-01",{"name":39,"class":40},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":41},"100579182","cric-combined-with-mft-for-cardiovascular-adverse-events-in-patients-with-incomplete-revascularization-of-cad-100579182","NCT06820970","CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD","Chronic Remote Ischemic Conditioning Combined With Mindfulness Therapy for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of Coronary Artery Disease: A Multicenter, Double-blind, Randomized Controlled Trial","CRCMF","Inclusion Criteria:\n\n* 1\\) Age ≥18 years old\n* 2\\) Consistent with the diagnosis of coronary heart disease, complete revascularization was not performed (coronary angiography showed that at least one vessel with a reference diameter of 3.0mm had stenosis greater than 90%, and quantitative flow ratio (QFR) \\\u003C 0.80)\n* 3\\) Symptoms of myocardial ischemia (resting or exertional angina; Angina allele: chest tightness, shortness of breath, etc.);\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) \\\u003C 30%\n* Creatinine clearance \\\u003C15 mL\u002Fmin (or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m²), or requires dialysis\n* Myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.\n* Uncontrolled or recurrent arrhythmic events (e.g., ventricular fibrillation, recurrent or symptomatic sustained ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular rates, supraventricular tachycardia refractory to drugs)\n* Poorly controlled hypertension (SBP \\> 180 mm Hg or DBP \\> 110 mm Hg)\n* Active liver disease or persistent ALT or AST elevation ≥ 3 times the upper limit of normal\n* Unexplained CK \\> 5 times the upper limit of normal, or elevated CK due to known muscle disease\n* Planned or anticipated cardiac surgery or revascularization before randomization\n* History of active malignancy (surgery, radiation therapy, and\u002For systemic therapy within the past 3 years)\n* Diagnosed or suspected upper extremity vascular malformations, aneurysms, arteriovenous fistulas, or thrombosis\n* Hearing impairment, unable to undergo mindfulness therapy\n* Currently participating in another drug or device study, or within 30 days of completing another drug or device study or receiving another investigational drug\n* Any life-threatening comorbid conditions expected to result in death within the next year (excluding cardiovascular diseases)\n* Alcoholism, substance abuse history; and unwilling or unable to stop alcohol or substance abuse during the study\n* History of major organ transplant (e.g., lung, liver, heart, bone marrow, kidney)\n* Investigator's judgment of known major active and uncontrolled disease, or any medical, physical, or surgical conditions (e.g., infection, significant blood, kidney, metabolic, gastrointestinal, or endocrine dysfunction) that may interfere with participation in the clinical study\n* As known to the investigator, the subject is unlikely to complete follow-up for more than 1 year or is expected to be unable to comply with the study requirements or understand the study's objectives and potential risks.",{"count":79,"type":22},2000,[53],"The main objective of this study is to demonstrate whether the combination of chronic remote ischemic conditioning and mindfulness therapy can reduce cardiovascular adverse events in patients with incomplete revascularization of coronary artery disease.",[83],"Coronary Artery Disease",{"date":85,"type":33},"2026-04-06",{"date":87,"type":33},"2025-08-01",{"date":89,"type":22},"2029-12-30",{"name":39,"class":40},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":41},"100420368","long-term-of-remote-ischemic-preconditioning-and-mindfulness-in-patients-with-mild-hypertension-100420368","NCT04753840","Long-term of Remote Ischemic Preconditioning and Mindfulness in Patients With Mild Hypertension","Inclusion Criteria:\n\n* Diagnosed patients with mild hypertension (SBP: 140\\~159mmHg; DBP: 90\\~99mmHg)\n\nExclusion Criteria:\n\n* Cannot tolerate RIPC\n* Non-essential hypertension\n* patients who have uncontrolled severe arrhythmia, diabetes, electrolyte disturbance\n* patients who have severe organic diseases such acute myocardial infarction, cardiac insufficiency, abnormal renal function, etc.","80 Years",{"count":99,"type":22},400,[53],"According to the latest survey data of China hypertension annual meeting, there are about 300 million patients with hypertension in China, with 10 million new cases of hypertension each year, and there is an obvious trend of younger people. In particular, young and middle-aged people are in a state of mild hypertension for a long time, which causes great pressure on health and medical treatment. At present, the main clinical measures for mild hypertension are to change their eating habits, quit smoking and alcohol, exercise and other lifestyle changes, as well as drug control. For most patients with mild hypertension, drug control is not the best choice. It has been reported that remote ischemic preconditioning (RIPC) may play an effective role in reducing blood pressure .The purpose of this study was to investigate the extent of long-term application of RIPC to reduce blood pressure in patients with mild hypertension.",[103],"Hypertension",{"date":85,"type":33},{"date":106,"type":33},"2021-07-03",{"date":108,"type":22},"2030-12-01",{"name":39,"class":40},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":128,"locationsCount":41},"100606884","effects-of-long-term-remote-ischemic-preconditioning-on-clinical-outcome-in-patients-with-acute-myocardial-infarction-100606884","NCT07181356","Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction","L-RICP-AMI","Inclusion Criteria:\n\n* Patients with acute myocardial infarction were diagnosed in accordance with the criteria of the \"Global Unified Definition of Fourth Myocardial Infarction\"\n\nExclusion Criteria:\n\n* The patients could not tolerate RIPC or RIPerC\n* Aortic dissection, coronary artery aneurysm, coronary artery fistula and other systemic organic diseases\n* The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively\n* severe liver dysfunction (bilirubin \\> 20 mmol \u002F L, prothrombin time \\> 2.0 ratio)\n* Severe renal insufficiency (GFR \\\u003C 30 ml \u002F min \u002F 1.73 m2);\n* patients taking nicorandil and other drugs affecting microcirculation\n* pregnant",{"count":118,"type":22},2146,[53],"At present, there are 290 million cardiovascular patients in China, including 11 million patients with coronary heart disease. Remote ischemic preconditioning(RIPC) may play an effective endogenous cardiac protection.This study will explore whether long-term use of RIPC in patients with AMI after PCI and non interventional therapy can reduce the incidence of major adverse cardiovascular cerebrovascular events(MACCE) and improve clinical outcomes and long-term prognosis.",[122],"Acute Myocardial Infarction","2025-09-12",{"date":125,"type":33},"2025-09-18",{"date":35,"type":33},{"date":68,"type":22},{"name":39,"class":40},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":41},"100422298","long-term-remote-ischemic-preconditioning-improves-myocardial-perfusion-and-prognosis-of-patients-after-cabg-100422298","NCT04779008","Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After CABG","Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After Coronary Artery Bypass Grafting","L-RIPC-CABG","Inclusion Criteria:\n\n* Three coronary artery lesions, CABG surgery was planned\n\nExclusion Criteria:\n\n* The patients could not tolerate ripc;\n* peripheral vascular disease affecting upper limbs\n* Acute myocardial infarction complicated with cardiogenic shock，in recent 30 days,\n* Emergency cases\n* Severe structural heart disease and severe arrhythmia ；\n* The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively;\n* Severe liver, renal and pulmonary disease\n* Mental disorder can't cooperate;\n* Inability to give informed consent；\n* Patients on glibenclamide or nicorandil, as these medications may interfere with RIC\n* pregnant;",{"count":138,"type":22},210,[53],"Remote Ischemic preconditioning (RIPC) has been reported to improve myocardial microcirculation, promote collateral circulation recruitment, and improve myocardial perfusion in patients.Two large randomized controlled trials demonstrated a perioperative cardioprotective effect of RIPC (reduced troponin levels), but did not find that a single preoperative RIPC improved long-term outcomes of coronary artery bypass grafting(CABG).The effect of a single RIPC before CABG may be too short. This study aims to investigate whether long-term RIPC improved myocardial perfusion in patients 3 months and 6 months after CABG surgery , and to detect changes in blood vascular endothelial growth factor, Nitrc Oxide, adenosine，and Endothelin-1, and to observe MACCE event rates at 12 months.",[56],{"date":125,"type":33},{"date":144,"type":33},"2021-03-10",{"date":146,"type":22},"2026-12-01",{"name":39,"class":40},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":159,"studyType":160,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":41},"100568048","an-observational-study-of-coronary-microvascular-disease-of-china-100568048","NCT06676137","An Observational Study of Coronary Microvascular Disease of China","China Coronary Microvascular Disease(CCMD) Registry","CCMD","Inclusion Criteria:\n\n1. Angina symptoms\n2. Objective evidence of myocardial ischemia\n3. Coronary angiography was normal,irregular tube wall, or stenosis \\\u003C50%\n\nExclusion Criteria:\n\n1. People under the age of 18\n2. Non-cardiogenic chest pain and other heart conditions such as variant angina, cardiomyopathy, myocarditis or valvular heart disease","85 Years",{"count":158,"type":22},500,"3 Years","OBSERVATIONAL","Non-obstructive coronary heart disease refers to patients with angina pectoris without significant narrowing of the epicardial vessels. Coronary microvascular disease(CMD) is a kind of non-obstructive coronary heart disease, and its clinical detection rate is increasing, seriously affecting the quality of life of patients, and increasing the risk of cardiovascular adverse events, but its mechanism has not been fully understood. This study will prospectively collect patients who meet the diagnosis of CMD, observe the development and outcome of the disease, and explore its occurrence and development mechanism.",[163],"Coronary Microvascular Disease","2025-08-19",{"date":166,"type":33},"2025-08-20",{"date":168,"type":33},"2024-11-11",{"date":170,"type":22},"2029-10-10",{"name":39,"class":40},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":41},"100601310","laparoscopic-adventitial-renal-denervation-rdn-for-refractory-hypertension-100601310","NCT07108829","Laparoscopic Adventitial Renal Denervation (RDN) for Refractory Hypertension","First-in-Man Clinical Study to Evaluate the Safety and Efficacy of Renal Artery Radiofrequency Ablation Clamp, Radiofrequency Ablation Generator for the Adjunctive Treatment of Refractory Hypertension and Drug-Intolerant Hypertension","Inclusion Criteria:\n\nAge ≥18 years and ≤65 years, any sex.\n\nDiagnosed with primary hypertension.\n\nHistory of hypertension for at least 6 months.\n\nBlood pressure meets the following two conditions:\n\nOffice systolic blood pressure ≥140mmHg and ≤180mmHg, and office diastolic blood pressure ≥90mmHg. If not taking a beta-blocker, resting heart rate must be ≥70bpm.\n\n24-hour ambulatory blood pressure measurement shows an average systolic pressure ≥130mmHg or a daytime average systolic pressure ≥135mmHg.\n\nHas a history of antihypertensive medication use within the last 6 months with uncontrolled blood pressure. Before enrollment, must undergo at least 28 days of a standardized medication regimen (including a diuretic and at least three drugs in total) with ≥80% compliance, while office SBP remains ≥140mmHg and ≤180mmHg, and office DBP remains ≥90mmHg.\n\nPatient is willing and able to comply with follow-up requirements and has signed the informed consent form.\n\nExclusion Criteria:\n\nSecondary hypertension.\n\nTarget renal artery anatomy is unsuitable, including:\n\nRenal artery diameter \\>9mm or \\\u003C4mm.\n\nMultiple renal arteries.\n\nSevere calcification, stenosis \\>50%, malformation, fibromuscular dysplasia, or aneurysm in either renal artery.\n\nHistory of renal artery intervention (e.g., balloon angioplasty or stenting).\n\nUnsuitable for laparoscopic surgery via the retroperitoneal approach, including prior retroperitoneal surgery, retroperitoneal fibrosis, or severe obesity (BMI \\> 40 kg\u002Fm²).\n\nHistory of kidney transplant or severe renal impairment (eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m²).\n\nHospitalization for a hypertensive crisis within the past year.\n\nSevere liver dysfunction (ALT or AST \\> 3 times the upper limit of normal).\n\nType 1 diabetes.\n\nHistory of a cardiovascular event (e.g., myocardial infarction, unstable angina) or cerebrovascular event (e.g., stroke, TIA) within the last 6 months.\n\nPregnancy or planning to become pregnant during the trial.\n\nParticipation in any other investigational drug or device trial within 3 months prior to screening.","65 Years",{"count":5,"type":22},[53],"This is a first-in-human study to test the safety and effectiveness of a new device-based treatment for high blood pressure that is difficult to control with medicine. This condition is known as refractory hypertension.\n\nThe study will enroll 10 adults aged 18 to 65 whose high blood pressure is not controlled even though they are taking three or more blood pressure medications.\n\nThe treatment involves a new medical device called a Renal Artery Radiofrequency Ablation Clamp. This device is used during a keyhole (laparoscopic) surgery. It works by applying controlled heat (radiofrequency energy) to the outside of the arteries that supply blood to the kidneys. This procedure, known as renal denervation, aims to calm the nerves around these arteries that contribute to high blood pressure.\n\nParticipants who join the study will first be monitored on a standard set of blood pressure medicines to confirm they are eligible. If they qualify, they will undergo the keyhole surgery. After the procedure, participants will be followed for 180 days (about 6 months) and will have several follow-up visits to check their blood pressure and overall health.",[184],"Refractory Hypertension or Drug-intolerant Hypertension",[103,186,187,188,189,190],"Resistant Hypertension","Renal Denervation","Laparoscopic","Radiofrequency Ablation","Sympathetic Nerves","2025-07-31",{"date":193,"type":33},"2025-08-07",{"date":195,"type":22},"2025-08",{"date":197,"type":22},"2026-08",{"name":39,"class":40},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":208,"conditions":209,"keywords":210,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":218,"locationsCount":41},"100563768","a-retrospective-study-on-the-factors-of-drug-coated-balloon-restenosis-100563768","NCT06620458","A Retrospective Study on the Factors of Drug-coated Balloon Restenosis","RE-DCB","Inclusion Criteria:\n\n* Age:\n\n  18 years and older.\n* Diagnosis:\n\nDiagnosed with coronary artery disease with native large vessel lesions confirmed by coronary angiography.\n\n* Treatment Plan:\n\nScheduled to receive paclitaxel drug-coated balloon angioplasty.\n\n* Informed Consent:\n\nPatients have been fully informed about the nature and purpose of the study, and have voluntarily agreed to participate, with signed informed consent.\n\n* Physiological Status:\n\nCardiac function classified as NYHA I-III.\n\nExclusion Criteria:\n\n* Allergy History:\n\nKnown allergies to paclitaxel or any materials used in angioplasty (e.g., contrast agents).\n\n* Severe Complications:\n\nUncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg).\n\n* Other Medical Conditions:\n\nActive bleeding or clotting disorders.\n\n* Other serious diseases with a life expectancy of less than 1 year (e.g., advanced cancer).\n* Pregnancy or Nursing: Women who are currently pregnant or breastfeeding.\n* Participation in Other Studies: Currently participating in other clinical trials that might affect the results of this study.\n* Psychological or Behavioral Factors: History of psychiatric or behavioral disorders that could interfere with adherence to study protocols, or communication barriers that prevent understanding of study requirements.",{"count":207,"type":22},5000,"The purpose of this study is to analyze potential factors post paclitaxel drug-coated balloon angioplasty in patients with Denovo large vessels disease. It includes imaging endpoints and clinical event endpoints. Over 5000 patients are expected to be enrolled.",[83],[211],"DCB CHD IVUS OCT","2024-11-12",{"date":214,"type":33},"2024-11-14",{"date":216,"type":33},"2024-10-01",{"date":146,"type":22},{"name":39,"class":40},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":226,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":41},"100529026","a-cohort-study-of-pci-strategies-for-severely-calcified-lesions-of-complex-coronary-arteries-in-the-elderly-100529026","NCT06168422","A Cohort Study of PCI Strategies for Severely Calcified Lesions of Complex Coronary Arteries in the Elderly","PSSCCE","Inclusion Criteria:\n\n1. Age ≥ 60 years;\n2. Meet the indications for coronary intervention;\n3. IVUS examination suggests severe calcified lesions (calcification angle \\>270°) or OCT examination suggests severe calcified lesions (calcification angle \\>180° and\u002For length \\>5mm and\u002For thickness \\>0.5mm);\n4. The diameter of the target lesion vessel is greater than 2.75mm;\n5. The total length of the lesion is more than 60mm and\u002For the number of lesions to be treated is ≥3 and\u002For the number of vessels to be treated is ≥2.\n\nExclusion Criteria:\n\n1. inability to provide written informed consent;\n2. inability to administer antiplatelet agents and anticoagulant therapy;\n3. the subject is participating in other unfinished clinical trials;\n4. life expectancy \\\u003C1 year;\n5. non-in situ vascular lesions;\n6. patients with haemodynamic instability;\n7. Previous stroke within 6 months.\n8. left main stem lesions.","60 Years",{"count":228,"type":22},2100,"The aim of this observational study is to compare the prognostic outcomes of various PCI strategies in elderly patients with complex coronary calcified lesions. The patients will be classified into two groups and assigned different PCI strategies, either stenting or stenting combined with pharmacologic balloon implantation. The investigators will assess the one-year prognosis for major adverse cardiovascular events in these patients.",[231],"Coronary Heart Disease","2024-06-25",{"date":234,"type":33},"2024-06-27",{"date":236,"type":33},"2023-12-25",{"date":238,"type":22},"2025-05-06",{"name":39,"class":40},""]